Track XORTX Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

XORTX Therapeutics Inc. Common Stock XRTX · Stock Open XORTX Therapeutics Inc. Common Stock in new tab

0.3950 USD
P/E
10.08
EPS
-2.58
P/B
1.14
ROE
-99.24
Beta
0.44
Loading chart...
Key Metrics
Earnings dateNov. 12, 2026
P/E10.08
EPS-2.58
Book Value1.50
Price to Book1.14
Debt/Equity1.17
% Insiders1.532%
Estimates
Forward P/E2.12
Forward EPS0.80

DCF Valuation

Tweak assumptions to recompute fair value for XORTX Therapeutics Inc. Common Stock (XRTX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

XORTX Therapeutics Inc. Common Stock Logo XORTX Therapeutics Inc. Common Stock Analysis (XRTX)

Canada Health Care Official Website Stock

Is XORTX Therapeutics Inc. Common Stock a good investment? XORTX Therapeutics Inc. Common Stock (XRTX) is currently trading at 0.3950 USD.

In terms of valuation, the stock trades at a P/E ratio of 10.08. This relatively low multiple may signal that XORTX Therapeutics Inc. Common Stock is undervalued compared to historical market norms.

Earnings Schedule: XORTX Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is 0.80.

Investor FAQ

Does XORTX Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is XORTX Therapeutics Inc. Common Stock?

XORTX Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -2.58.

Company Profile

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

Exchange Ticker
NMS (United States) XRTX
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2014
0.00 USD
Feb. 17, 2014 0.0001
▸2013
0.00 USD
Nov. 1, 2013 0.0001
July 30, 2013 0.0001
May 2, 2013 0.0001
▸2012
0.00 USD
Dec. 31, 2012 0.0001
Oct. 30, 2012 0.0001
Aug. 1, 2012 0.0001
April 26, 2012 0.0001
Feb. 29, 2012 0.0001
▸2011
0.00 USD
Dec. 9, 2011 0.0001
Aug. 26, 2011 0.0001
Stock Splits
Split Date Split Ratio to 1
Nov. 10, 2023 0.11
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion